Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Agios today announced that the U.S. FDA has approved AQVESME™ (mitapivat), an oral pyruvate kinase (PK) activator, for thalassemia
-
Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia
-
Agios today announced financial results and updates for the third quarter ended September 30, 2025.
-
Agios today announced that the CHMP has adopted a positive opinion for the new indication for PYRUKYND in adults for anemia associated with thalassemia
-
New York, USA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight The thalassemia market is...
-
Agios announced that the U.S. FDA has extended the PDUFA goal date for the sNDA of PYRUKYND for adults with thalassemia by three months to December 7, 2025
-
Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia
-
Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.
-
EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent...
-
Agios Pharmaceuticals, Inc. today reported business highlights and financial results for the first quarter ended March 31, 2025.